Automated insulin delivery among adults with type 1 diabetes for up to 2 years: a real-world, multicentre study.
automated insulin delivery
closed-loop systems
glucose time in range
glycated haemoglobin
type 1 diabetes
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
31 May 2023
31 May 2023
Historique:
received:
23
12
2022
accepted:
16
05
2023
pubmed:
31
5
2023
medline:
31
5
2023
entrez:
31
5
2023
Statut:
aheadofprint
Résumé
Automated insulin delivery (AID) improves glycaemia among people with type 1 diabetes in clinical trials and overseas real-world studies. Whether improvements are sustained beyond 12 months in the real world, and whether they occur in the Australian context, has not yet been established. We aimed to observe, up to 2 years, the effectiveness of initiating first-generation AID for type 1 diabetes management. Retrospective, real-world, observational study using medical records, conducted across five sites in Australia. Adults with type 1 diabetes, who had AID initiated between February 2019 and December 2021, were observed for 6-24 months after initiation (until June 2022). Outcomes examined included glucose metrics assessed by glycated haemoglobin (HbA Ninety-four adults were studied (median age 39 years (interquartile range, IQR: 31-51); pre-initiation HbA Early glucose improvements were observed after real-world AID initiation, sustained up to 2 years, without excess adverse events. The greatest benefits were observed among individuals with highest glycaemia before initiation. Future-generation systems with increased user-friendliness may enhance therapy continuation.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Automated insulin delivery (AID) improves glycaemia among people with type 1 diabetes in clinical trials and overseas real-world studies. Whether improvements are sustained beyond 12 months in the real world, and whether they occur in the Australian context, has not yet been established. We aimed to observe, up to 2 years, the effectiveness of initiating first-generation AID for type 1 diabetes management.
METHODS
METHODS
Retrospective, real-world, observational study using medical records, conducted across five sites in Australia. Adults with type 1 diabetes, who had AID initiated between February 2019 and December 2021, were observed for 6-24 months after initiation (until June 2022). Outcomes examined included glucose metrics assessed by glycated haemoglobin (HbA
RESULTS
RESULTS
Ninety-four adults were studied (median age 39 years (interquartile range, IQR: 31-51); pre-initiation HbA
CONCLUSIONS
CONCLUSIONS
Early glucose improvements were observed after real-world AID initiation, sustained up to 2 years, without excess adverse events. The greatest benefits were observed among individuals with highest glycaemia before initiation. Future-generation systems with increased user-friendliness may enhance therapy continuation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : St Vincent's Hospital Melbourne
Informations de copyright
© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Diabetes Control and Complications Trial Research Group, Nathan D, Genuth S, Lachin J, Cleary P, Crofford O et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
Pease AJ, Andrikopoulos S, Abraham MB, Craig ME, Fenton B, Overland J et al. Utilisation, access and recommendations regarding technologies for people living with type 1 diabetes: consensus statement of the ADS/ADEA/APEG/ADIPS Working Group. Med J Aust 2021; 215: 473-8.
Thabit H, Hovorka R. Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia 2016; 59: 1795-805.
Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015; 373: 2129-40.
Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019; 381: 1707-17.
McAuley SA, Lee MH, Paldus B, Vogrin S, de Bock MI, Abraham MB et al. Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: a randomized, controlled trial. Diabetes Care 2020; 43: 3024-33.
Abraham MB, De Bock M, Smith GJ, Dart J, Fairchild JM, King BR et al. Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes. JAMA Pediatr 2021; 175: 1227.
Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM. One year clinical experience of the first commercial hybrid closed-loop system. Diabetes Care 2019; 42: 2190-6.
Berget C, Messer LH, Vigers T, Frohnert BI, Pyle L, Wadwa RP et al. Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the 670G system. Pediatr Diabetes 2020; 21: 310-18.
Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell-Bergeon J et al. Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: identifying a clinical target for hybrid closed-loop use. Diabetes Obes Metab 2021; 23: 2048-57.
Breton MD, Kovatchev BP. One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther 2021; 23: 601-8.
Da Silva J, Bosi E, Jendle J, Arrieta A, Castaneda J, Grossman B et al. Real-world performance of the MiniMed™ 670G system in Europe. Diabetes Obes Metab 2021; 23: 1942-9.
DuBose SN, Bauza C, Verdejo A, Beck RW, Bergenstal RM, Sherr J. Real-world, patient-reported and clinic data from individuals with type 1 diabetes using the MiniMed 670G hybrid closed-loop system. Diabetes Technol Ther 2021; 23: 791-8.
Jacobsen SS, Hommel E, Ranjan AG, Norgaard K. Glycemic effects and predictors of increased time-in-range after initiating MiniMed 670G: a 12-month observational study. Diabetes Technol Ther 2022; 24: 592-7.
Toschi E, Atakov-Castillo A, Slyne C, Munshi M. Closed-loop insulin therapy in older adults with type 1 diabetes: real-world data. Diabetes Technol Ther 2022; 24: 140-2.
Usoh CO, Johnson CP, Speiser JL, Bundy R, Dharod A, Aloi JA. Real-world efficacy of the hybrid closed-loop system. J Diabetes Sci Technol 2022; 16: 659-62.
Pease AJ, Zoungas S, Callander E, Jones TW, Johnson SR, Holmes-Walker DJ et al. Nationally subsidized continuous glucose monitoring: a cost-effectiveness analysis. Diabetes Care 2022; 45: 2611-19.
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019; 42: 1593-603.
Cheung NW, Conn JJ, D'Emden MC, Gunton JE, Jenkins AJ, Ross GP et al. Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J Aust 2009; 191: 339-44.
Arunachalum S, Velado K, Vigersky RA, Cordero TL. Glycemic outcomes during real-world hybrid closed-loop system use by individuals with type 1 diabetes in the United States. J Diabetes Sci Technol 2022: 193229682210886.
Living Evidence for Diabetes Consortium. Australian Evidence-Based Clinical Guidelines for Diabetes. Melbourne, Australia: Living Evidence for Diabetes Consortium; 2020.
Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care 2015; 38: 971-8.
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, Dimeglio LA et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther 2019; 21: 66-72.
McAuley SA, Trawley S, Vogrin S, Ward GM, Fourlanos S, Grills CA et al. Closed-loop insulin delivery versus sensor-augmented pump therapy in older adults with type 1 diabetes (ORACL): a randomized, crossover trial. Diabetes Care 2022; 45: 381-90.
Messer LH, Berget C, Vigers T, Pyle L, Geno C, Wadwa RP et al. Real world hybrid closed-loop discontinuation: predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediatr Diabetes 2020; 21: 319-27.
National Diabetes Services Scheme. Eligibility Expansion for all People with Type 1 Diabetes to Access Subsidised CGM and Flash GM Products through the NDSS. Australia: National Diabetes Services Scheme; 2022. https://www.ndss.com.au/news/eligibility-expansion-for-all-people-with-type-1-diabetes-to-access-subsidised-cgm-and-flash-gm-products-through-the-ndss/ Accessed 11 May, 2023.
Johnson SR, Holmes-Walker DJ, Chee M, Earnest A, Jones TW, the CGM Advisory Committee and Working Party and the ADDN Study Group. Universal subsidized continuous glucose monitoring funding for young people with type 1 diabetes: uptake and outcomes over 2 years, a population-based study. Diabetes Care 2022; 45: 391-7.